KRAS and non-small cell lung carcinoma: All six treatment analyses across various treatment types (i.e., ICI, non-ICI, or KRAS G12C inhibitor) resulted in a significantly worse OS (p < 0.05) for SMARCA4/KRAS-co-mutated NSCLC patients.